Therapy: Blockade of IGF-1R-Not effective in neuroendocrine tumours

Nature Reviews Endocrinology

Volumn 9, Issue 7, 2013, Pages 389-390

  Libutti, Steven K ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; DALOTUZUMAB; EVEROLIMUS; GANITUMAB; OCTREOTIDE; PLACEBO; SOMATOMEDIN; SOMATOMEDIN RECEPTOR; SOMATOSTATIN DERIVATIVE; SUNITINIB;

CANCER INCIDENCE; DISEASE COURSE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SHORT SURVEY;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; NEUROENDOCRINE TUMORS; RECEPTOR, IGF TYPE 1;

EID: 84879410601     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2013.109     Document Type: Short Survey

References (10)

1. Strosberg, J. et al. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumours. Endocr. Relat. Cancer 20, 383-390 (2013).
2. Spiegel, A. M. & Libutti, S. K. Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors. Nat. Rev. Clin. Oncol. 8, 258-259 (2011).
3. Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514-523 (2011).
4. Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumours. N. Engl. J. Med. 364, 501-513 (2011).
5. Höpfner, M., Baradari, V., Huether, A., Schöfl, C. & Scherübl, H. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr. Relat. Cancer 13, 135-149 (2006).
6. Vitale, L. et al. Differential expression of alternatively spliced mRNA forms of the insulinlike growth factor 1 receptor in human neuroendocrine tumors. Oncol. Rep. 15, 1249-1256 (2006).
7. Tolcher, A. W. et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol. 27, 5800-5807 (2009).
8. Reidy-Lagunes, D. L. et al. A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer 118, 4795-4800 (2012).
9. Shen, H. C. et al. Recapitulation of pancreatic neuroendocrine tumours in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1. Cancer Res. 69, 1858-1866 (2009).
10. Quinn, T. J. et al. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumours (PNETs) in a multiple endocrine neoplasia type 1(MEN1) conditional knockout mouse model. Surgery 152, 1068-1077 (2012).